Lantus (Insulin Glargine)

Insulin glargine binds to insulin receptors, promoting glucose uptake in muscle and fat cells while suppressing hepatic glucose production. After subcutaneous injection it forms microprecipitates that release insulin slowly, giving a steady, peak‑less effect for up to 24 hours.

The dose of Lantus is individualized and set by the prescribing healthcare professional based on the patient’s blood‑glucose readings, body weight, diet, and other therapies. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Safety data for insulin glargine in pregnancy and lactation are limited. It may be used when the expected benefit to the mother outweighs potential risks to the fetus or infant. Decisions should be made by the treating physician in consultation with the patient.

To order Lantus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and import documentation.

Lantus (insulin glargine) offers a 24‑hour, peak‑less profile similar to other basal insulins such as insulin detemir or degludec. Compared with detemir, glargine often requires once‑daily dosing, whereas detemir may need twice‑daily dosing in some patients. Choice depends on individual response, dosing convenience, and clinician preference.

Lantus should be stored in a refrigerator at 2‑8 °C. Keep the vial in its original carton, protect it from light, and do not freeze or shake the solution. Once in use, the vial may be kept at room temperature (up to 30 °C) for up to 28 days, but any cloudiness or particles indicate it should be discarded.

Lantus is given as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection should be performed using a sterile needle, rotating sites to avoid lipodystrophy. It is usually administered once daily at the same time each day, but the exact schedule is determined by the prescriber.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical attention for any signs of a severe allergic response.

Lantus is contraindicated in individuals with a known hypersensitivity to insulin glargine or any of its excipients. Patients who have experienced severe allergic reactions to other insulin preparations should also avoid its use until evaluated by a healthcare professional.